Skip to content

Science
Investor
About
Learn
Contact

Science
Investor
About
Learn
Contact

Investor Alerts

Investor

News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Year Keywords

Advanced Search

Search

Search Headlines Only

From

To

Asset Types

Photos Video Audio Documents Events Standard

Jan 9, 2017

InMed Launches New Website
Dec 23, 2016

InMed Provides 2016 Year End Update
Dec 15, 2016

InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier
Dec 6, 2016

InMed announces progress on COPD program
Nov 23, 2016

InMed to Present at Cannabis-Based Therapies Conference
Oct 31, 2016

InMed Pharmaceuticals, Inc. Appoints Senior Vice President, Clinical and Regulatory Affairs
Oct 27, 2016

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000
Oct 4, 2016

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$1,500,000
Sep 13, 2016

InMed Appoints Andrew Hull to the Board of Directors
Sep 12, 2016

InMed to Present at 18th Annual Rodman and Renshaw Global Investment Conference
Jul 28, 2016

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$304,500
Jul 19, 2016

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$250,000
Jun 16, 2016

InMed Announces Appointment of Eric A. Adams as CEO, President and Director
Jun 13, 2016

InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors
May 18, 2016

InMed Updates Progress of its Epidermolysis Bullosa Program
May 4, 2016

InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures
Feb 16, 2016

InMed Announces Update on Biosynthesis Project
Nov 23, 2015

InMed Strengthens Board with Appointment of Experienced Biotech Executive Adam Cutler
Nov 4, 2015

InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa
Nov 2, 2015

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000
Sep 3, 2015

InMed Appoints Paul Brennan as President & Chief Executive Officer
Sep 2, 2015

InMed Commences Development of Proprietary Drug Delivery System
Aug 25, 2015

InMed Appoints Paul Brennan to the Board of Directors
Aug 20, 2015

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Aug 6, 2015

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)

Show 5 10 25 50 100 per page

«
1
2
3
4
5
6
»

Investor Alerts

Sign up for investor alerts!

Information Request

Send us a request for information

Stay up to Date

Subscribe to all of our investor information, including news, events, presentations and more

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Science

INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
INM-405 for Orofacial Pain
Biosynthesis Platform
InMed’s Research of Rare Cannabinoids

Investor

News Releases
Latest Presentation
Letter to Shareholders
SEDAR^® Filings
Financial Reports

About

Management
Board of Directors
Scientific Advisory Board
Corporate Governance
Careers

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

Sign Up For Investor Alerts

© Copyright 2020 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On: